Brief: Enveric Biosciences Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
28/08/2025 13:33
Aug 28 (Reuters) - Enveric Biosciences Inc ENVB.O: ENVERIC BIOSCIENCES INC - COMPLETES PRE-IND DOSE RANGE FINDING STUDIES FOR LEAD CANDIDATE EB-003 Source text: ID:nBw12C4nya Further company coverage: ENVB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003